Xyphos

Executive Summary

Xyphos Biosciences, a South San Francisco-based biotechnology company founded in 2016, is developing a novel platform for flexible and controllable immune cell therapies targeting cancer. The company's core technology centers on engineered immune cells that can be precisely regulated to enhance anti-tumor activity while minimizing off-target effects, potentially overcoming key limitations of current cell therapies such as antigen escape and toxicity. Xyphos aims to deliver adaptable, next-generation cancer treatments that could revolutionize patient care. While the company operates in stealth mode with limited public disclosures, its platform approach positions it within the rapidly evolving cell therapy landscape, where controllability and safety are critical unmet needs. Xyphos has not yet disclosed specific lead programs, clinical candidates, or funding rounds, but its focus on programmable cell therapies aligns with industry trends toward more sophisticated synthetic biology applications in oncology. The company's progress will depend on demonstrating preclinical proof-of-concept and securing partnerships or financing to advance toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead program60% success
• H1 2027Series A or B financing round70% success
• 2028IND filing for first candidate30% success